Nexocare Biotech Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.12 M
- Company Age 10 Year, 11 Days
- Last Filing with ROC 31 Mar 2020
- Revenue Growth 53.87%
- Profit Growth 183.96%
- Ebitda 359.44%
- Net Worth 8.80%
- Total Assets 64.48%
About Nexocare Biotech
Nexocare Biotech Private Limited (NBPL) is a Private Limited Indian Non-Government Company incorporated in India on 30 January 2015 and has a history of Ten years. Its registered office is in Chandigarh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2020. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.12 M, as per Ministry of Corporate Affairs (MCA) records.
Babli and Suresh Kumar serve as directors at the Company.
Company Details
-
Location
Chandigarh, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24232CH2015PTC035400
-
Company No.
035400
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
30 Jan 2015
-
Date of AGM
31 Dec 2020
-
Date of Balance Sheet
31 Mar 2020
-
Listing Status
Unlisted
-
ROC Code
Roc Chandigarh
Industry
What products or services does Nexocare Biotech Private Limited offer?
Nexocare Biotech Private Limited offers a wide range of products and services, including Nutraceuticals & Dietary Supplements, Dietary Supplements, Common Disease Medicines, Pharmaceutical Syrup, Digestive System Drugs & Medicines, Antacid Drugs.
Who are the key members and board of directors at Nexocare Biotech?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Babli
|
Director | 09-Feb-2021 | Current |
|
Suresh Kumar
|
Director | 30-Jan-2015 | Current |
Financial Performance of Nexocare Biotech.
Nexocare Biotech Private Limited, for the financial year ended 2019, experienced significant growth in revenue, with a 53.87% increase. The company also saw a substantial improvement in profitability, with a 183.96% increase in profit. The company's net worth moved up by a moderate rise of 8.8%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nexocare Biotech?
In 2019, Nexocare Biotech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Nexocare Biotech?
Unlock and access historical data on people associated with Nexocare Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nexocare Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nexocare Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
